Evidence of Target Engagement and Modulation: Biomarker Analysis of the Phase 1b Inhaled Seralutinib Study

Evidence of Target Engagement and Modulation: Biomarker Analysis of the Phase 1b Inhaled Seralutinib Study

PHA – June 2022

Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).

PROSERA clinical trial: NCT05934526

Learn more about the study